A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of 1 directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical studies.

No abstract

Design and Synthesis of Tricyclic Derivatives as High Density Lipoprotein Cholesterol Enhancers. -The synthesis and evaluation of imidazoisoquinolones [cf. (Va), (Vb)], related pyrimidoisoquinolones [cf. (VII)], and imidazonaphthyridines [cf. (Vc)] as high density lipoprotein cholesterol enhancing compounds is described. The synthetic route involves a novel and widely applicable one-step preparation of 3-carboxamidophthalides (III) from 2-acylbenzoic acids (I). -(ELOKDAH, HASSAN; CHAI, SIE-YEARL; HO,

1 The short rabbit pulmonary artery was denuded of endothelium and divided into three sections, the cardiac end (cardiac), middle and pulmonary end (pulmonary) sections, respectively. Des-Aspangiotensin I attenuated the contractions of the cardiac and middle sections to transmural nerve stimulation but potentiated the contractions in the pulmonary section. 2 The actions of the nonapeptide were inhibited completely by 10-6 M losartan; however, a similar concentration of PD123319 had no effect. Indomethacin (10-6 M) also inhibited completely the attenuation in the cardiac and middle sections but had no effect on the potentiation seen in the pulmonary section. 3 The data suggest that the two differential responses of the pulmonary artery to des-Asp-angiotensin I are mediated by two separate subtypes of the losartan-sensitive angiotensin AT1 receptor.

No abstract